Further to our letter dated May 14, 2026, whereby the Company had submitted the link of audio recording of the Q4 & FY26 Earning Conference Call on the Financial Results for the fourth ....
VIDHIING · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vidhi Specialty Food Ingredients delivered a resilient FY26 performance despite global headwinds including tariffs and geopolitical tensions. Revenue stood at INR380 crores (flat YoY), but EBITDA improved significantly to INR78 crores from INR68 crores, with margins expanding from 17.91% to 20.52%. Net profit grew 10.80% to INR49.15 crores. The company highlighted its strategic shift toward high-value, specialty products, with margins on manufacturing sales at ~24-25%. Key growth initiatives include the CoatIcon pharma tablet coating range (INR5-12 crores capex) in aggressive customer qualification, and a new product line at Dahej (INR75-85 crores capex) expected to generate INR125-150 crores sales. High-value products currently represent 5% of portfolio, targeted to reach 10-12% in FY27. Management expects full utilization of both Dahej and Roha facilities in FY27, with the new product line commissioned by mid-FY28.
The company's margin expansion despite revenue stagnation demonstrates successful product mix optimization toward higher-value segments. The planned INR80-97 crores total capex signals meaningful future growth but will require careful capital allocation monitoring. Investors should watch for the ramp-up of specialty products and new product line commercialization over the next 18-24 months.